Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse.

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Huntington's disease (HD) is a neurodegenerative disorder.
• Transgenic mouse models are crucial for studying HD.
• The R6/1 mouse model expresses exon 1 of the human HD gene with a 115 CAG repeat.

Purpose of the Study:

• To characterize the R6/1 mouse model for Huntington's disease.
• To establish and compare semi-quantitative biomarkers for HD.
• To validate the R6/1 mouse as a model for therapeutic evaluation.

Main Methods:

• Behavioral assessments including motor coordination, general activity, anxiety, and developmental instability.
• Molecular analyses measuring cannabinoid receptor 1 mRNA, peptide, and protein levels, as well as neuronal inclusions.
• Longitudinal study of female hemizygotic R6/1 transgenic mice and wildtype littermates from 6 to 36 weeks of age.

Main Results:

• Cannabinoid receptor 1 (CB1) mRNA downregulation observed between 8-10 weeks.
• Early behavioral phenotypes like feetclasping emerged at 14 weeks, with significant individual variation.
• Progressive developmental instability (fluctuating asymmetry) noted from 11 weeks; weight differences by 22 weeks.
• Significant motor impairments in open field and plus-maze tests at 23-24 weeks.
• No significant abnormalities in stride length were detected.

Conclusions:

• The R6/1 mouse model exhibits a progressive neurological phenotype relevant to Huntington's disease.
• Key molecular and behavioral biomarkers can be semi-quantitatively measured.
• The R6/1 model demonstrates variability, highlighting the need for careful study design.
• This model is suitable for preclinical evaluation of drugs and therapies for Huntington's disease.